According to Zacks, “CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. “
Other equities analysts have also recently issued research reports about the company. HC Wainwright restated a buy rating on shares of Cyclacel Pharmaceuticals in a report on Wednesday, May 15th. Roth Capital restated a buy rating on shares of Resverlogix in a report on Thursday, May 23rd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Cyclacel Pharmaceuticals currently has an average rating of Buy and a consensus price target of $5.50.
CYCC remained flat at $$0.55 on Tuesday. 753 shares of the company were exchanged, compared to its average volume of 80,662. The business’s fifty day moving average price is $0.57. The company has a market cap of $9.37 million, a P/E ratio of -0.89 and a beta of 2.94. Cyclacel Pharmaceuticals has a 12-month low of $0.51 and a 12-month high of $1.87. The company has a quick ratio of 8.09, a current ratio of 8.09 and a debt-to-equity ratio of 0.08.
Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.04. Analysts expect that Cyclacel Pharmaceuticals will post -0.63 earnings per share for the current year.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.
Featured Article: The components of the Stochastic Momentum Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.